Linkedin
RLS logo_header
Linkedin

Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015

“Since our founding, SciBrunch has remained focused on advancing innovative therapies targeting the RAS pathway and is committed to delivering transformative treatment options for patients with pancreatic, colorectal, lung, and other major malignant tumors,” said Tao Hu, founder, chairman and chief executive officer of SciBrunch. “This agreement with Merck not only validates the R&D strength of our platform but also underscores the potential of SPR2015 in addressing longstanding unmet medical needs in oncology. We are excited that Merck, a global leader in oncology, will take SPR2015 forward.”

Read the full story on "Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015"

Share:

More News

Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in Oncology

Jian Peng, PhD, CEO of Earendil Labs, said: “Genentech is a pioneer in defining modern biologics cancer medicine. Earendil Labs is building an AI-driven high-throughput biology platform that effectively integrates AI directly into biologics research and development—from predictive protein modeling and generative protein design to rapid experimental validation. By combining

IDMC Recommends Continued Ph 2 Development of IMNN-001 Following Favorable Safety Review

“The IDMC’s recommendation to continue our Phase 2 MRD study without modification provides important independent validation of the favorable safety profile we have consistently observed across our clinical development program,” said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “Across our completed and ongoing clinical studies, we have

Results Announced for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Ph 3 EXCALIBER-RRMM Trial in RRMM Patients

“These Phase 3 results reinforce the potential of ZENBEXUS to advance treatment for patients with relapsed or refractory multiple myeloma,” said Cristian Massacesi, executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “As the first therapy in multiple myeloma to demonstrate superiority on an MRD-negative complete

IND-enabling studies for BEA 17 initiated in GBM

“Initiating IND-enabling studies is a defining milestone for Beactica and for the BEA‑17 programme,” said Dr Per Källblad, Chief Executive Officer of Beactica Therapeutics. “With a first-in-class mechanism and compelling preclinical efficacy in combination with standard of care, we are now executing the rigorous safety and manufacturing programme that will